论文部分内容阅读
研究目的:乙肝是尚未解决的公众健康问题,需要开发新型抗病毒药物。本研究拟从天然植物绿茶中寻找有效、经济、毒副作用低的抗乙肝病毒药物。创新要点:首次以HepG2 2.2.15细胞为载体,发现EGCG对乙肝病毒HBsAg、HBeAg和HBV DNA的选择性作用。研究方法:采用酶联免疫吸附实验(ELISA)检测细胞上清中HBsAg和HBeAg的含量,采用反转录聚合酶链反应(RT-PCR)检测上清和细胞内HBV DNA的含量。重要结论:EGCG的浓度在0.11~0.44μmol/ml(即50~200μg/ml)的范围内能有效抑制HepG2 2.2.15细胞中HBsAg和HBeAg的分泌,其效果甚至优于浓度为0.87μmol/ml(即200μg/ml)的拉米夫定(3TC),并且具有时间和剂量依赖性。同时,EGCG也能抑制胞外HBV DNA的表达。研究结果表明,EGCG具有良好抗病毒活性和低毒副作用,有望开发成为一种新的抗病毒药物。
Research purposes: Hepatitis B is an unresolved public health problem that requires the development of novel antiviral drugs. This study intends to look for green tea from natural plants effective, economical, low side effects of anti-hepatitis B virus drugs. Innovative points: For the first time to HepG2 2.2.15 cells as a carrier, found EGCG on hepatitis B virus HBsAg, HBeAg and HBV DNA selective role. Methods: The contents of HBsAg and HBeAg in the supernatant of the cells were detected by enzyme-linked immunosorbent assay (ELISA), and the content of HBV DNA in supernatant and intracellular were detected by reverse transcription-polymerase chain reaction (RT-PCR). Important conclusion: EGCG concentration in the range of 0.11 ~ 0.44μmol / ml (ie 50 ~ 200μg / ml) can effectively inhibit the secretion of HBsAg and HBeAg in HepG2 2.2.15 cells, the effect is even better than the concentration of 0.87μmol / ml (Ie, 200 [mu] g / ml) lamivudine (3TC) and in a time and dose dependent manner. At the same time, EGCG also inhibits the expression of extracellular HBV DNA. The results show that EGCG has good antiviral activity and low toxicity and is expected to be developed into a new antiviral drug.